Pet Medicine, Pet Supplies , Animals & Pet Supplies Allergy Treatments MSD
MSD Numelvi Tablets for Dogs

MSD

MSD

MSD

MSD

MSD Numelvi Tablets for Dogs

£1.06
Dogs

Upload Prescription *

Choose File
MSD Numelvi Tablets for Dogs are the only second-generation Janus Kinase (JAK) inhibitor for the treatment of pruritus associated with allergic dermatitis, including atopic dermatitis, and clinical manifestations of atopic dermatitis in dogs. It's approved for dogs from six months of age.
Accredited Retailer of Veterinary Medicines

Description

MSD Numelvi Tablets for Dogs offer a revolutionary, once-daily solution for dogs suffering from the discomfort of allergic dermatitis, including atopic dermatitis. As the first and only second-generation Janus Kinase (JAK) inhibitor, Numelvi provides rapid and effective relief from pruritus, or itching, making life much more comfortable for your beloved pet. Its targeted action ensures a favourable safety profile, and it can be used alongside regular vaccinations and other common treatments, simplifying your dog's care routine. Pet owners will appreciate the ease of a single daily tablet and the quick onset of action, with itch relief beginning within hours.

This product is ideal for dogs suffering from allergic dermatitis, including atopic dermatitis, who experience persistent itching and associated clinical signs. It is suitable for dogs from six months of age.

Not recommended for dogs under six months of age or weighing less than 3kg. This is a prescription-only veterinary medicine (POM-V) and should only be used under the guidance of a veterinary professional.

See more

Key Benefits

  • Only second-generation Janus Kinase (JAK) inhibitor for the treatment of pruritus associated with allergic dermatitis, including atopic dermatitis, and treatment of clinical manifestations of atopic dermatitis in dogs.
  • Approved for use in dogs as young as six months of age and 3kg.
  • Offers a rapid onset of action, beginning to relieve itch within 2-4 hours.
  • Provides simple, once-daily dosing from day one.
  • Highly selective for JAK1, contributing to a favourable safety profile.
  • Can be used concurrently with vaccines (including rabies) and other common treatments such as ectoparasiticides.
  • No requirement for routine blood and urine monitoring.